We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’

By LabMedica International staff writers
Posted on 21 Mar 2025
Print article
Image: Inpeco’s new open automation system FlexLab X will enable Grifols solutions to interconnect with, and expand within, existing and future lab footprints (Photo courtesy of Inpeco)
Image: Inpeco’s new open automation system FlexLab X will enable Grifols solutions to interconnect with, and expand within, existing and future lab footprints (Photo courtesy of Inpeco)

Grifols (Barcelona, Spain), a manufacturer of plasma-derived medicines and innovative diagnostic solutions, has entered into a strategic agreement with Inpeco (Novazzano, Switzerland), a global leader in total laboratory automation technologies, to provide transfusion medicine labs with complete, tailored instrumentation, robotics, and software capabilities to modernize their operations and make them more efficient.

The partnership adds to Grifols’ global leadership in instrumentation, reagents and technical service that screens blood and plasma for possible pathogens as well as performs blood typing for safer transfusions. Grifols, whose technology analyzes tens of millions of donor samples each year, now complements its portfolio with Inpeco’s new open automation system FlexLab™ X, a combination of leading-edge robotics and software that will enable Grifols solutions to interconnect with, and expand within, existing and future lab footprints.

Specifically, Grifols will enhance its industry-leading analytical technologies known for their high throughput and precision with Inpeco’s iconic automation solutions that dispatch sample tubes to Grifols analyzers, among others, and then, after testing, route them to refrigerated storage to further reduce manual intervention while guaranteeing full sample traceability. Digital dashboards provide real-time data on lab performance, while flexible architecture allows to adopt innovations still to come. As part of their collaboration, the two companies are exploring areas in which their combined engineering expertise could deliver more value to transfusion medicine laboratories, which could include technologies that focus on sample pooling, analysis, and transport.

“Grifols is providing the laboratory of the future,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “We are extremely pleased to join forces with Inpeco, two global lab technology leaders with a complete solution for labs of any size to fully equip their operations knowing they will have the most advanced and scalable technologies today and in the future.”

“At Inpeco, we believe that end-to-end automation is the key to eliminating errors in diagnostic processes,” said Riccardo Triunfo, CEO of Inpeco. “Especially in transfusion medicine, where precision is non-negotiable, our mission is to ensure that labs operate with the highest levels of safety, efficiency and accuracy. Our partnership with Grifols reinforces this vision, enabling laboratories to modernize their operations with confidence.”

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: Microscopic images showing healthy villi on the left and diseased villi on the right (Photo courtesy of Florian Jaeckle/University of Cambridge)

Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read more
Sekisui Diagnostics UK Ltd.